To determine the accuracy of quantitative SPECT, intersystem and interpatient standardized uptake value (SUV) calculation consistency for a manufacturer-independent quantitative SPECT/CT reconstruction algorithm, and the range of SUVs of normal and neoplastic tissue. A NEMA body phantom with 6 spheres (ranging 10–37 mm) was filled with a known activity-to-volume ratio and used to determine the contrast recovery coefficient (CRC) for each visible sphere, and the measured SUV accuracy of those spheres and background water solution. One hundred eleven 123I-metaiodobenzylguanidine ([I-123] mIBG) SPECT/CT examinations from 43 patients were reconstructed using SUV SPECT® (HERMES Medical Solutions Inc.); 42 examinations were acquired using a GE Infinia Hawkeye 4 SPECT/CT, and 69 were acquired on a Siemens Symbia Intevo SPECT/CT. Inter scanner SUV analysis of 9 regions of normal [I-123] mIBG tissue uptake was conducted. Intrapatient mean SUV variability was calculated by measuring normal liver uptake within patients scanned on both cameras. The intensity of uptake by neoplastic tissue in the images was quantified using maximum SUV and, if present, compared over time. The phantom results of the visible spheres and background resulted in accuracy calculations better than 5–10% with CRC correction. Interscanner SUV variability showed no statistical difference (average p value 0.559; range 0.066–1.0) among the 9 normal tissues analyzed. Intrapatient liver mean SUV varied ≤ 16% as calculated for 28 patients (87 examinations) studied on both scanners. In one patient, a thoracic tumor evaluated over 10 time points (18 months) underwent a 74% (3.1/12.0) reduction in maximum SUV with treatment. The results demonstrate quantitative accuracy to better than 10%, and both consistent SUV calculation between 2 different SPECT/CT scanners for 9 tissues, and low intrapatient measurement variability for quantitative SPECT/CT analysis in a pediatric population with neuroblastoma. Quantitative SPECT/CT offers the opportunity for objective analysis of tumor response using [I-123] mIBG by normalizing the uptake to injected dose and patient weight, as is done for PET.

中文翻译：

---

幻影和成神经细胞瘤患者中定量[I-123] mIBG SPECT / CT的分析

为了确定定量SPECT的准确性，系统间和患者间标准化摄取值（SUV）的计算一致性，适用于制造商无关的定量SPECT / CT重建算法，以及正常和赘生组织的SUV范围。用6个球体（范围为10-37 mm）的NEMA人体模型填充已知的活动体积比，并用于确定每个可见球体的对比度恢复系数（CRC）以及这些球体和背景水溶液。使用SUVSPECT®（HERMES Medical Solutions Inc.）重建了来自43例患者的111个123I-蛋氨酸苄基胍（[I-123] mIBG）SPECT / CT检查；使用GE Infinia Hawkeye 4 SPECT / CT进行了42次检查，而使用Siemens Symbia Intevo SPECT / CT进行了69次检查。扫描仪SUV分析了正常[I-123] mIBG组织摄取的9个区域。通过测量在两个摄像机上扫描的患者的正常肝摄取量，计算出患者的SUV平均变异性。使用最大SUV量化图像中肿瘤组织的摄取强度，如果存在，则将其随时间进行比较。可见球体和背景的幻像结果导致使用CRC校正的精度计算优于5-10％。Interscanner SUV的变异性在9个正常组织中无统计学差异（平均p值0.559；范围0.066–1.0）。根据在两个扫描仪上研究的28位患者（87次检查）的计算，患者的肝内SUV平均≤16％。在一名患者中，在10个时间点（18个月）评估的胸腔肿瘤接受了74％（3.1 / 12）的治疗。0）通过治疗减少最大SUV。结果表明定量准确性优于10％，并且在2种不同的SPECT / CT扫描仪之间针对9种组织的SUV计算一致，并且在患神经母细胞瘤的儿科人群中进行SPECT / CT定量分析的患者术中测量变异性较低。SPECT / CT定量分析为通过[I-123] mIBG标准化肿瘤对注射剂量和患者体重的摄取提供了客观分析肿瘤反应的机会，就像对PET一样。